18889881171
Kalkine 0
countryflagUS

Biogen Inc

Healthcare US BIIB

131.79USD
-0.52(0.39%)

Last update at 2025-06-13T16:49:00Z

Day Range

130.55132.49
LowHigh

52 Week Range

153.62268.30
LowHigh

Fundamentals

  • Previous Close 132.31
  • Market Cap22778.80M
  • Volume322972
  • P/E Ratio14.13
  • Dividend Yield-%
  • EBITDA2885.00M
  • Revenue TTM9607.50M
  • Revenue Per Share TTM66.12
  • Gross Profit TTM 7895.10M
  • Diluted EPS TTM11.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 3591.80M 1745.20M 5047.50M 7125.90M 5899.60M
Minority interest 85.30M 171.50M 59.90M -4.10000M 43.30M
Net income 3046.90M 1556.10M 4000.60M 5888.50M 4430.70M
Selling general administrative 2403.60M 2623.60M 2504.00M 2374.70M 2106.30M
Selling and marketing expenses - - - - -
Gross profit 7895.10M 8872.00M 11639.40M 12422.50M 11636.60M
Reconciled depreciation 365.90M 487.70M 457.20M 680.60M 1016.60M
Ebit 2320.20M 2840.70M 4550.10M 7042.60M 6113.00M
Ebitda 2686.10M 3656.60M 4807.30M 7518.70M 6860.30M
Depreciation and amortization 365.90M 815.90M 257.20M 476.10M 747.30M
Non operating income net other 614.50M -1060.60000M 502.70M 3.90M 11.00M
Operating income 2320.20M 2840.70M 4550.10M 7042.60M 5888.60M
Other operating expenses 7271.50M 8173.70M 8998.30M 7342.20M 7452.10M
Interest expense 246.60M 253.60M 222.50M 187.40M 200.60M
Tax provision 632.80M 52.50M 992.30M 1158.00M 1425.60M
Interest income 89.30M 11.00M 42.00M 120.00M 112.50M
Net interest income -157.30000M -242.60000M -180.50000M -67.40000M -88.10000M
Extraordinary items - - - - -23.70000M
Non recurring 131.10M 18.00M 75.00M 1.50M 124.50M
Other items - - - - -
Income tax expense 632.80M 52.50M 992.30M 1158.00M 1425.60M
Total revenue 10173.40M 10981.70M 13444.60M 14377.90M 13452.90M
Total operating expenses 4993.20M 6064.00M 7193.10M 5386.80M 5635.80M
Cost of revenue 2278.30M 2109.70M 1805.20M 1955.40M 1816.30M
Total other income expense net 1271.60M -1095.50000M 497.40M 83.30M -101.20000M
Discontinued operations - - - - -
Net income from continuing ops 2961.60M 1692.70M 4055.20M 5967.90M 4474.00M
Net income applicable to common shares 3046.90M 1556.10M 4000.60M 5888.50M 4430.70M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 26844.80M 24554.10M 23877.30M 24618.90M 27234.30M
Intangible assets 8363.00M 1850.10M 2221.30M 3084.30M 3527.40M
Earning assets - - - - -
Other current assets 1182.00M 1417.60M 1153.10M 1294.60M 1221.20M
Total liab 12045.40M 11165.70M 12917.60M 13932.80M 13895.20M
Total stockholder equity 14799.40M 13388.40M 10959.70M 10686.10M 13339.10M
Deferred long term liab - 334.70M 694.50M 1032.80M 2810.80M
Other current liab 838.40M 2781.30M 3299.10M 3287.30M 3368.00M
Common stock 0.10M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.10M 0.10M 0.10M 0.10M 0.10M
Retained earnings 17627.60M 16466.50M 13911.70M 13976.30M 16455.40M
Other liab - 1278.90M 2015.00M 2362.40M 4159.70M
Good will 6219.20M 5749.00M 5761.10M 5762.10M 5757.80M
Other assets - 1652.90M 3354.60M 4196.00M 3232.10M
Cash 1049.90M 3419.30M 2261.40M 1331.20M 2913.70M
Cash and equivalents - - - - -
Total current liabilities 3434.30M 3272.80M 4298.20M 3742.20M 4863.80M
Current deferred revenue 2042.60M - -589.20000M - -530.80000M
Net debt 6288.30M 3194.70M 5342.10M 6497.00M 3453.80M
Short term debt 150.00M - 999.10M 7426.00M 1495.80M
Short long term debt 150.00M - 999.10M - 1495.80M
Short long term debt total 7338.20M 6614.00M 7603.50M 7828.20M 6367.50M
Other stockholder equity -2674.60000M -2913.30000M -2845.40000M -2991.30000M -2981.20000M
Property plant equipment - 3298.60M 3416.40M 3411.50M 3247.30M
Total current assets 6859.30M 9791.20M 7856.50M 6887.10M 8381.80M
Long term investments 0.00000M 2234.90M 892.00M 772.10M 1408.10M
Net tangible assets - 5798.80M 2913.80M 1853.90M 4058.00M
Short term investments 0.00000M 1473.50M 1541.10M 1278.90M 1562.20M
Net receivables 2100.00M 2136.40M 1549.40M 1913.80M 1880.50M
Long term debt 6788.20M 6281.00M 6274.00M 7426.20M 4459.00M
Inventory 2527.40M 1344.40M 1351.50M 1068.60M 804.20M
Accounts payable 403.30M 491.50M 589.20M 454.90M 530.80M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - -9.50000M 63.50M -14.20000M -4.10000M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -153.70000M -164.90000M -106.70000M -299.00000M -135.20000M
Additional paid in capital - - - - -
Common stock total equity - 0.10M 0.10M 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - 16466.50M 13911.70M 13976.30M 16455.40M
Treasury stock - -2977.10000M -2977.10000M -2977.10000M -2977.10000M
Accumulated amortization - - - - -
Non currrent assets other 284.30M 1529.20M 1941.00M -1369.50000M -3232.10000M
Deferred long term asset charges - - - - 3232.10M
Non current assets total 19985.50M 14762.90M 16020.80M 17731.80M 18852.50M
Capital lease obligations 400.00M 333.00M 330.40M 402.00M 412.70M
Long term debt total - 6281.00M 6274.00M 7426.20M 4459.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -4101.00000M 1576.60M -309.80000M -29.90000M 1233.70M
Change to liabilities - -347.70000M -9.10000M -50.40000M 213.00M
Total cashflows from investing activities - 1576.60M -563.70000M -608.60000M 470.50M
Net borrowings - -1002.20000M -170.00000M 1467.40M 1467.40M
Total cash from financing activities 149.30M -1759.70000M -2086.20000M -5272.70000M -5860.40000M
Change to operating activities - -224.40000M -238.70000M 193.80M 133.60M
Net income 1161.50M 2961.60M 1727.60M 4060.50M 5888.50M
Change in cash -2369.40000M 1157.90M 930.20M -1582.50000M 1689.10M
Begin period cash flow 3419.30M 2261.40M 1331.20M 2913.70M 1224.60M
End period cash flow 1049.90M 3419.30M 2261.40M 1331.20M 2913.70M
Total cash from operating activities 1547.20M 1384.30M 3639.90M 4229.80M 7078.60M
Issuance of capital stock - - - - -
Depreciation 494.80M 518.40M 487.70M 457.20M 680.60M
Other cashflows from investing activities - 604.10M 4.20M -153.90000M -248.70000M
Dividends paid - - 0.70M 4.60M -
Change to inventory -130.90000M -320.20000M -462.40000M -316.30000M -19.20000M
Change to account receivables 61.30M -203.40000M 324.80M 2.80M 68.80M
Sale purchase of stock 0.00000M -750.00000M -1800.00000M -6679.10000M -5868.30000M
Other cashflows from financing activities -38.00000M 4.90M -114.80000M 2915.60M 7.90M
Change to netincome - -1471.30000M 743.30M 673.60M 254.90M
Capital expenditures 311.40M 243.20M 294.90M 551.80M 669.50M
Change receivables - -203.40000M 324.80M 2.80M 68.80M
Cash flows other operating - 246.90M 828.00M -597.60000M -8.00000M
Exchange rate changes - - - - 0.40M
Cash and cash equivalents changes - 1213.60M 990.00M -1651.50000M 1689.10M
Change in working capital -648.70000M -890.30000M -145.50000M -187.20000M 199.30M
Stock based compensation 264.20M 254.10M 238.60M 198.30M 182.30M
Other non cash items 581.20M -1290.90000M 1758.30M -448.00000M 60.80M
Free cash flow 1235.80M 1141.10M 3345.00M 3678.00M 6409.10M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIIB
Biogen Inc		 -0.52 0.39% 131.79 14.13 9.20 2.37 1.39 2.89 9.92
LLY
Eli Lilly and Company		 11.51 1.42% 823.54 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 1.01 0.64% 157.67 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 - -% 192.42 61.52 14.86 5.62 51.62 6.76 20.58
MRK
Merck & Company Inc		 0.42 0.51% 82.24 59.83 12.33 4.50 6.47 4.94 23.79

Reports Covered

Stock Research & News

View All

Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc

225 Binney Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Michael R. McDonnell CPA Exec. VP & CFO 1964
Ms. Susan H. Alexander Esq. Exec. VP, Chief Legal Officer & Sec. 1957
Mr. Christopher A. Viehbacher Pres, CEO & Director 1960
Ms. Robin C. Kramer Sr. VP & Chief Accounting Officer 1966
Ms. Nicole Murphy Head of Pharmaceutical Operations & Technology NA
Mr. Michael Hencke Head of Investor Relations NA
Ms. Natacha Gassenbach Chief Communication Officer & Head of Corp. Affairs NA
Dr. Ginger Gregory Exec. VP & Chief HR Officer 1968
Dr. Anabella Villalobos Ph.D. Head of Biotherapeutics & Medicinal Sciences 1959
Dr. Sanjay Jariwala Sr. VP of Worldwide Medical NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.